KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Accumulated Expenses (2016 - 2025)

Astrazeneca (AZN) has 3 years of Accumulated Expenses data on record, last reported at $7.3 billion in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 12.3% year-over-year to $7.3 billion; the TTM value through Dec 2025 reached $7.3 billion, up 12.3%, while the annual FY2025 figure was $7.3 billion, 12.3% up from the prior year.
  • Accumulated Expenses reached $7.3 billion in Q4 2025 per AZN's latest filing, up from $6.5 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $7.3 billion in Q4 2025 and bottomed at $6.1 billion in Q4 2023.
  • Average Accumulated Expenses over 3 years is $6.6 billion, with a median of $6.5 billion recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: increased 5.74% in 2024, then grew 12.3% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $6.1 billion in 2023, then increased by 5.74% to $6.5 billion in 2024, then increased by 12.3% to $7.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $7.3 billion in Q4 2025, $6.5 billion in Q4 2024, and $6.1 billion in Q4 2023.